



Case Type

Zantac (Ranitidine)



General Background

Ranitidine, also known by the brand name Zantac, is used for the treatment and prevention of heartburn, ulcers, and other throat and stomach conditions. It is available both by prescription and over-the-counter.

In April 2020, the FDA issued a recall of Zantac after finding a cancer-causing chemical called N-Nitrosodimethylamine (NDMA). NDMA modifies DNA, causing inflammation that results in tumor growth and promotion. FDA testing confirmed that NDMA contamination can increase over time while in normal storage conditions and significantly increase under high temperatures. Thus, the older the Zantac tablet, the greater the contamination of NDMA. Since these findings, thousands of Zantac lawsuits have been filed by people who took the product and later developed a range of cancers.

There are two main claims being made in the Zantac lawsuits. The first is that the product's formula is defective because its active ingredient, ranitidine, is an unstable molecule that can become highly toxic. The second issue being raised in the Zantac lawsuits is that the manufacturer tried to downplay the risk of cancer by not providing sufficient warnings on the product label.

Criteria

- Have taken Zantac for at least one year prior to cancer diagnosis
- Have used Zantac at least once a week for six months or longer
- Been diagnosed with bladder, stomach, esophageal, liver, or pancreatic cancer
- Been diagnosed with cancer at 89 years of age or younger
- Developed cancer within 20 years of the last time you took Zantac

Qualifying Injuries

- Bladder Cancer
- Liver Cancer
- Stomach (Gastric) Cancer
- Esophageal Cancer
- Pancreatic Cancer